{
Merck KGaA

Companies

}
global clinical biomarkers market projected to reach 47 billion by 2031
The global clinical biomarkers market, valued at $25.02 billion in 2023, is projected to reach $47.25 billion by 2031, growing at a CAGR of 8.54%. This growth is driven by rising cancer cases and advancements in diagnostic technologies, despite challenges like high costs and reimbursement issues. Key players include Roche, Abbott, and Johnson & Johnson, with significant developments in biomarker testing for various diseases.
openPR.com
Eurofins Scientific S.E. A PerkinElmer Inc Johnson & Johnson Services Inc. Bio-Rad Laboratories, Inc. Qiagen N.V. Merck KGaA Thermo Fisher Scientific Inc. General Electric Co Siemens Healthineers AG Agilent Technologies, Inc. F. Hoffmann-La Roche Ltd. USA Show more
Healthcare, Market Report
08:45 16.12.2024
global cell freezing media market poised for significant growth by 2033
The global cell freezing media market is projected to exceed $387.5 million by 2033, growing at a CAGR of 9.66% from 2023. North America is expected to dominate the market due to advanced healthcare infrastructure, while Asia-Pacific is anticipated to experience the fastest growth, driven by low costs and a focus on biologics manufacturing. Key players include Thermo Fisher Scientific and Merck, with innovations in cryopreservation techniques fueling market expansion.
Spherical Insights
United States Dollar Hemacare Company Capricorn Scientific GmbH Sartorius Aktiengesellschaft Cellular Applications, Inc. PromoCell GmbH Himedia Laboratories Ltd. Merck KGaA BioLife Solutions, Inc. Mediatech, Inc. Thermo Fisher Scientific Inc. Nippon Genetics AMSBIO USA QAT DEU ITA FRA MEX ARG AUS ZAF IND SAU RUS JPN KOR GBR BRA CAN ARE ESP CHN Show more
Healthcare, Market Report
04:05 19.11.2024
Merck shares analyzed with buy recommendation from UBS AG
Merck shares are currently priced at €144.45, reflecting a decrease of €1.55 or 1.06%. UBS AG has issued a buy recommendation for the stock, indicating positive expectations for its performance in the near future.
finanzen.net
Euro Merck KGaA DEU
TradFi, Market Report
11:47 15.11.2024
ubs maintains buy rating for merck with target price of 190 euros
UBS has maintained a "Buy" rating for Merck KGaA, setting a target price of 190 euros after the recent quarterly figures, which showed few surprises. Despite a 1.1% drop in share price to EUR 144.90, the stock has risen 2.0% since the start of 2024, indicating potential for growth. The Q4 2024 balance sheet is anticipated on March 6, 2025.
finanzen.ch
Euro Merck KGaA UBS AG CHE DEU Matthew Weston
TradFi, Market Report
11:37 15.11.2024
ubs maintains buy rating for merck kgaa with target price of 190 euros
UBS has maintained a 'Buy' rating for Merck KGaA, setting a target price of 190 euros following the company's quarterly figures. Analyst Matthew Weston noted that the results showed few surprises after the recent capital market day. Merck KGaA is a leading global pharmaceutical and chemical company, with diverse sales across various product families and regions.
MarketScreener
Euro Merck KGaA USA DEU CHN Matthew Weston Show more
TradFi, Market Report
11:33 15.11.2024
ubs maintains buy rating for merck kgaa with target price of 190 euros
UBS has maintained a 'Buy' rating for Merck KGaA, setting a target price of 190 euros following the release of quarterly figures. Analyst Matthew Weston noted that the key figures presented few surprises after the recent capital market day.
boerse.de
Euro Merck KGaA DEU Matthew Weston
TradFi, Market Report
10:46 15.11.2024
ubs maintains buy rating for merck with target price of 190 euros
UBS AG has maintained a "Buy" rating for Merck KGaA, setting a target price of 190 euros following the latest quarterly figures. Despite a 1.2% decline in share price to EUR 144.70, there remains a potential upside of 31.31%. The company is set to release its Q4 2024 results on March 6, 2025.
finanzen.net
Euro Merck KGaA UBS AG DEU Matthew Weston
TradFi, Market Report
10:37 15.11.2024
UBS maintains buy rating for Merck KGaA with target price of 190 euros
UBS has maintained a "Buy" rating for Merck KGaA, setting a target price of 190 euros following the company's third-quarter results. While sales met market expectations, the adjusted EBITDA exceeded forecasts due to reduced research spending in the healthcare sector, although this trend may not continue. Overall, the results did not present any significant surprises.
boerse.de
Euro Merck KGaA UBS AG CHE DEU Matthew Weston
TradFi, Market Report
13:35 14.11.2024
ubs maintains buy rating for merck kgaa with target price of 190 euro
UBS has reiterated its 'Buy' rating for Merck KGaA, setting a target price of 190 Euros. Investors are cautioned about the significant risks associated with trading financial instruments and cryptocurrencies, which can lead to substantial losses. It is advisable to seek independent financial advice before engaging in such trading activities.
Investing.com Deutsch
Euro Merck KGaA DEU
TradFi, Market Report
13:35 14.11.2024
ubs maintains buy rating for merck with target price of 190 euros
UBS AG has maintained a "Buy" rating for Merck KGaA, setting a target price of €190 following the third-quarter results, which met expectations. Despite a 1.8% drop in share price to €148.75, the stock shows a potential upside of 27.73%. The upcoming Q3 2024 figures are due on November 14, 2024.
finanzen.ch
Euro Merck KGaA UBS AG DEU Matthew Weston
TradFi, Market Report
11:52 14.11.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Corporate Responsibility & ESG Central Bank Actions Decentralized Finance (DeFi) Innovations Cryptocurrency & Blockchain Regulations Tokenomics and Crypto Economics Banking Regulations Cryptocurrency Regulations Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Funding Rounds & Investments Mergers & Acquisitions Cryptocurrency Developments SEC & Financial Compliance Inflation Rates & CPI Data Real Estate Investments Shareholder Activism
Countries:
USA CHE JPN AUS CAN IND GBR DEU AUT CHN HKG RUS LIE SAU BHR FRA ARG COL FIN NLD
Companies:
Coinbase Global, Inc. Ripples USD Solana USD BlackRock, Inc. Ethereum USD NVIDIA Corporation Cardano USD Tesla, Inc. Apple Inc. Credit Suisse Real Estate Fund Siat MicroStrategy Incorporated Amazon.com, Inc. Sumitomo Corp Google Inc. Bitwise Bitcoin ETF Chainlink USD Palantir Technologies Inc. Tether USDt CNY VAT Group AG Northern Star Resources Ltd
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Canadian Dollar Colombian Peso Singapore Dollar Indian Rupee
People:
Ali Martinez Donald Trump Michael J. Saylor Elon Musk Charles Hoskinson Bill Gates Fred Thiel Jack Dorsey Jacob King Brian Armstrong Aaron Green Gary Gensler Karin Keller-Sutter Mario Nawfal Alan Santana Richard Schueler Roger J. Hamilton Steven Rossi Jane Dietze Brian P. Brooks

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.